Drugs / TEZEMLIMOGENE DAXADENOREPVEC
TEZEMLIMOGENE DAXADENOREPVEC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04714983 | Feb 2021 → Jul 2026 | ampulla of vater cancer, breast cancer, gastric cancer, gastrointestinal stromal tumor +5 | DNAtrix, Inc. | Suspended | No outcome recorded |
| Phase 1 | NCT03714334 | Oct 2018 → Apr 2023 | adult glioblastoma | Clinica Universidad de Navarra, Universidad de Navarra | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZEMLIMOGENE DAXADENOREPVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095328 ↗ |
| Known as | DNX-2440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03714334 ↗ |
| Known as | Tezemlimogen daxadenorepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095328 ↗ |
| Route | Other | “DNX-2440 virus will be injected stereotactically” NCT03714334 ↗ |